Adult and Adolescent Vaccines Market to 2017 - Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010

GBI Research, August 2011, Pages: 118

“Adult and Adolescent Vaccines Market to 2017 – Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010”, which provides insights into the global vaccines market, forecast until 2017. The report provides an in-depth analysis of five vaccines, which include pneumococcal, seasonal flu, human papillomavirus, hepatitis A and hepatitis B. The report also examines the immunization schedules for the covered vaccines. In addition, the report also includes insights into the vaccines R&D pipeline.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by a team of industry experts.

This analysis shows that the overall global vaccines market was valued at $28 billion in 2010. The market is expected to witness growth at a CAGR of 11.5% for the forecast period, and will reach $56.7 billion by 2017. The global market revenues are expected to increase due to the introduction of new molecules which are currently in the regulatory filing stage, and those in the later stages of development. The top pharmaceutical companies in the vaccines market are GlaxoSmithKline, Sanofi, Pfizer, Novartis AG., Merck & Co. Inc, and SP-MSD. Approximately 88% of the market is covered by these six companies.

Scope

- Data and analysis on the global adult and adolescent vaccines market

- Annualized market data for the adult and adolescent vaccines market from 2007 to 2017 for pneumococcal vaccines, human pappilomavirus vaccines, seasonal flu vaccines, hepatitis A vaccines and hepatitis B vaccines

- Key drivers and restraints that have had a significant impact on the market

- The competitive landscape of the global vaccines market

- Key M&A activities, licensing agreements and co-development deals that took place in the vaccines market between 2009 and 2011.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.

- Devise a more tailored country strategy through the understanding of key drivers and barriers of the vaccines market.

- Develop key strategic initiatives by understanding the key focus areas and leading companies.

- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

1.1 List of Tables
1.2 List of Figures

2 Adult and Adolescent Vaccines Market to 2017: Introduction
2.1 Overview
2.2 GBI Research Report Guidance

3 Adult and Adolescent Vaccines Market to 2017: Market Overview
3.1 Vaccine Preventable Diseases
3.2 Vaccine Manufacturing Process

4 Adult and Adolescent Vaccines Market to 2017: Global Vaccines Market
4.1 Market Forecasts
4.2 Market Share by Diseases Sector
4.3 Market Share by Geography
4.4 Average Cost of Vaccination per Child
4.5 Target Population
4.6 Immunization Coverage
4.7 Unmet Needs
4.8 Market Trends
4.8.1 Immunization Programs
4.8.2 Public Private Partnerships
4.8.3 Production Capacity
4.8.4 Reimbursements
4.9 Drivers
4.9.1 Growth will be Driven by Vaccines Targeting New Diseases
4.9.2 The Adult Vaccines Segment will Provide a Significant Boost to Growth of the Market
4.9.3 Pediatric Combination Vaccines will Continue to Drive Growth
4.9.4 Availability of Vaccine Technologies That Help Increase Efficacy and Safety will Drive Innovation and Growth
4.9.5 Cancer and HIV/AIDS Vaccines Hold Significant Potential for the Future
4.10 Barriers
4.10.1 Limitations in Production Capacity Delay the Realization of Potential
4.10.2 High Initial Capital Investments and Technical Expertise Act as Entry Barriers
4.10.3 Lack of Harmonized Regulations Delays Vaccine Launch and Acceptance

5 Adult and Adolescent Vaccines Market to 2017: The US Vaccines Market
5.1 Market Overview
5.2 Market Forecasts
5.3 Cost of Vaccination per Child in the US
5.4 Immunization Schedule
5.5 Regulatory Framework
5.6 Vaccine Procurement
5.7 Vaccine Stockpiling

6 Adult and Adolescent Vaccines Market to 2017: European Vaccines Market
6.1 Market Overview
6.2 Market Forecasts
6.3 Average Cost of Vaccination per Child
6.4 Vaccine Stockpiling
6.5 The UK
6.5.1 Immunization Schedule
6.5.2 Regulatory Framework
6.5.3 Vaccine Procurement
6.6 France
6.6.1 Immunization Schedule
6.6.2 Regulatory Framework
6.6.3 Vaccine Procurement
6.7 Germany
6.7.1 Immunization Schedule
6.7.2 Regulatory Framework
6.7.3 Vaccine Procurement
6.8 Italy
6.8.1 Immunization Schedule
6.8.2 Regulatory Framework
6.8.3 Vaccine Procurement
6.9 Spain
6.9.1 Immunization Schedule
6.9.2 Regulatory Framework
6.9.3 Vaccine Procurement

7 Adult and Adolescent Vaccines Market to 2017: Rest of the World Vaccines Market
7.1 Market Overview
7.2 Market Forecasts
7.3 Average Cost of Vaccination per Child
7.4 Immunization Schedule
7.5 Regulatory Framework
7.6 Vaccine Procurement
7.7 Vaccine Stockpiling

8 Adult and Adolescent Vaccines Market to 2017: Pneumococcal Vaccines Market
8.1 Market Overview
8.2 Market Forecasts
8.3 Average Cost of Vaccination
8.4 Target Population
8.5 Immunization Coverage
8.6 Product Analysis
8.6.1 Prevnar 7
8.6.2 Prevnar 13 (pneumococcal 13-valent conjugate vaccine)
8.6.3 Pneumovax 23
8.6.4 Synflorix
8.7 Vaccine Pipeline Analysis
8.7.1 Phase lll
8.7.2 Phase ll
8.7.3 Phase l
8.7.4 Preclinical/Discovery

9 Adult and Adolescent Vaccines Market to 2017: Human Pappilomavirus Vaccines Market
9.1 Market Overview
9.2 Market Forecasts
9.3 Average Cost of Vaccination
9.4 Target Population
9.5 Immunization Coverage
9.6 Product Analysis
9.6.1 Gardasil
9.6.2 Cervarix
9.7 Vaccine Pipeline Analysis
9.7.1 Phase lll
9.7.2 Phase ll
9.7.3 Phase l
9.7.4 Preclinical/Discovery

10 Adult and Adolescent Vaccines Market to 2017: Seasonal Flu Vaccines Market
10.1 Market Overview
10.2 Average Cost of Vaccination
10.3 Target Population
10.4 Immunization Coverage
10.5 Product Analysis
10.5.1 Fluzone
10.5.2 Fluarix
10.6 Vaccine Pipeline Analysis
10.6.1 Regulatory Filed Products
10.6.2 Phase lll
10.6.3 Phase ll
10.6.4 Phase l
10.6.5 Preclinical/Discovery

11 Adult and Adolescent Vaccines Market to 2017: Hepatitis A Vaccines Market
11.1 Market Overview
11.2 Market Forecasts
11.3 Average Cost of Vaccination
11.4 Target Population
11.5 Product Analysis
11.5.1 Twinrix
11.5.2 Havrix
11.5.3 Vaqta
11.5.4 Ambirix
11.5.5 Avaxim
11.6 Vaccine Pipeline Analysis
11.6.1 NDA Filed Molecules
11.6.2 Phase lll
11.6.3 Preclinical/Discovery

12 Adult and Adolescent Vaccines Market to 2017: Hepatitis B Vaccines Market
12.1 Market Overview
12.2 Market Forecasts
12.3 Average Cost of Vaccination
12.4 Target Population
12.5 Product Analysis
12.5.1 Recombivax HB
12.5.2 Engerix-B
12.5.3 Twinrix
12.5.4 Comvax
12.6 Vaccine Pipeline Analysis
12.6.1 Regulatory Filed Products
12.6.2 Phase lll
12.6.3 Phase ll
12.6.4 Phase l
12.6.5 Preclinical/Discovery

13 Adult and Adolescent Vaccines Market to 2017: Competitive Landscape
13.1 Overview
13.2 Market Share Analysis

14 Adult and Adolescent Vaccines Market to 2017: Strategic Consolidations
14.1 Mergers & Acquisitions
14.1.1 Overview
14.1.2 Top Deals in M&A
14.1.3 M&A by Indication
14.1.4 M&A by Year
14.1.5 M&A by Geography
14.1.6 M&A by Value
14.2 Licensing Agreements
14.2.1 Overview
14.2.2 Top Licensing Deals
14.2.3 Licensing Deals by Indication
14.2.4 Licensing Deals by Year
14.2.5 Licensing Deals by Geography
14.2.6 Licensing Deals by Value
14.3 Co-Development Deals
14.3.1 Overview
14.3.2 Top Co-Development Deals
14.3.3 Co-Development Deals by Indication
14.3.4 Co-Development Deals by Year
14.3.5 Co-Development Deals by Geography
14.3.6 Co-Development Deals by Value

15 Appendix
15.1 Market Definitions
15.2 Abbreviations
15.3 Research Methodology
15.4 Global Vaccines Market
15.4.1 Coverage
15.4.2 Sources of Coverage
15.4.3 Methodology
15.5 Geographical Landscape
15.5.1 Coverage
15.5.2 Sources of Coverage
15.5.3 Methodology
15.6 Market Characterization
15.6.1 Coverage
15.6.2 Sources of Coverage
15.6.3 Methodology
15.7 Competitive Landscape
15.7.1 Coverage
15.7.2 Sources of Coverage
15.7.3 Methodology
15.8 Pipeline Analysis
15.8.1 Coverage
15.8.2 Sources of Coverage
15.8.3 Methodology
15.9 Strategic Consolidations
15.9.1 Coverage
15.9.2 Sources of Coverage
15.9.3 Methodology
15.10 Contact Us
15.11 Disclaimer
15.12 Sources

1.1 List of Tables

Table 1: Adult and Adolescent Vaccines Market to 2017, Vaccine Preventable Disease, 2010
Table 2: Adult and Adolescent Vaccines Market to 2017, Global, Revenues ($bn), 2007-2017
Table 3: Adult and Adolescent Vaccines Market to 2017, Global, Market Share By Indication (%), 2010
Table 4: Adult and Adolescent Vaccines Market to 2017, Global, Target Pediatric Population (‘000), 2007-2017
Table 5: Adult and Adolescent Vaccines Market to 2017, Global, Target Adult Population (‘000), 2007-2017
Table 6: Adult and Adolescent Vaccines Market to 2017, Global, Immunization Coverage (%), 2007-2009
Table 7: Adult and Adolescent Vaccines Market to 2017, Global, GAVI Achievements, 2008-2010
Table 8: Adult and Adolescent Vaccines Market to 2017, the US, Revenues ($bn), 2007-2017
Table 9: Adult and Adolescent Vaccines Market to 2017, the US, Cost of Vaccination ($), 2010
Table 10: Adult and Adolescent Vaccines Market to 2017, Europe, Revenues ($bn), 2007-2017
Table 11: Adult and Adolescent Vaccines Market to 2017, Europe, Average Cost of Vaccination ($), 2009
Table 12: Adult and Adolescent Vaccines Market to 2017, Rest of the World, Revenues ($bn), 2007-2017
Table 13: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Revenues ($bn), 2007-2017
Table 14: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Annual Cost of Vaccination ($), 2007-2017
Table 15: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Target Population (‘000), 2007-2017
Table 16: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccines, Phase lll Molecules, 2011
Table 17: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccines, Phase ll Molecules, 2011
Table 18: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccines, Phase l Molecules, 2011
Table 19: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccines, Preclinical / Discovery Molecules, 2011
Table 20: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Revenues ($bn), 2007-2017
Table 21: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Annual Cost of Vaccination ($), 2007-2017
Table 22: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Target Population (‘000), 2007-2017
Table 23: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Product Comparison, 2007-2017
Table 24: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Phase lll Molecules, 2011
Table 25: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Phase ll Molecules, 2011
Table 26: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Phase l Molecules, 2011
Table 27: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Preclinical / Discovery Molecules, 2011
Table 28: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Revenues ($bn), 2007-2017
Table 29: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Annual Cost of Vaccination ($), 2007-2017
Table 30: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Target Population (‘000), 2007-2017
Table 31: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Regulatory Filed Molecules, 2011
Table 32: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Phase lll Molecules, 2011
Table 33: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Phase ll Molecules, 2011
Table 34: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Phase l Molecules, 2011
Table 35: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Preclinical / Discovery Molecules, 2011
Table 36: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Revenues ($m), 2007-2017
Table 37: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Annual Cost of Vaccination ($), 2007-2017
Table 38: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Target Population (million), 2007-2017
Table 39: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccines, NDA Filed Molecules, 2011
Table 40: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccines, Phase lll Molecules, 2011
Table 41: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccines, Preclinical / Discovery Molecules, 2011
Table 42: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Revenues ($m), 2007-2017
Table 43: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Annual Cost of Vaccination ($), 2007-2017
Table 44: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Target Population (million), 2007-2017
Table 45: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Regulatory Filed Molecules, 2011
Table 46: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Phase lll Molecules, 2011
Table 47: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Phase ll Molecules, 2011
Table 48: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Phase l Molecules, 2011
Table 49: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Preclinical / Discovery Molecules, 2011
Table 50: Adult and Adolescent Vaccines Market to 2017, Global, Top Deals in M&A (%), 2009-2011
Table 51: Adult and Adolescent Vaccines Market to 2017, M&A by Indication (%), 2009-2011
Table 52: Adult and Adolescent Vaccines Market to 2017, M&A by Year (%), 2009-2011
Table 53: Adult and Adolescent Vaccines Market to 2017, M&A by Geography (%), 2009-2011
Table 54: Adult and Adolescent Vaccines Market to 2017, M&A by Value (%), 2009-2011
Table 55: Adult and Adolescent Vaccines Market to 2017, Global, Top Licensing Deals ($m), 2009-2011
Table 56: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Indication (%), 2009-2011
Table 57: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Year (%), 2009-2011
Table 58: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Geography (%), 2009-2011
Table 59: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Value (%), 2009-2011
Table 60: Adult and Adolescent Vaccines Market to 2017, Global, Co-Development Deals, 2009-2011
Table 61: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Indication (%), 2009-2011
Table 62: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Year (%), 2009-2011
Table 63: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Geography (%), 2009-2011
Table 64: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Value (%), 2009-2011

1.2 List of Figures

Figure 1: Adult and Adolescent Vaccines Market to 2017, Global, Vaccine Manufacturing Process, 2010
Figure 2: Adult and Adolescent Vaccines Market to 2017, Global, Revenues ($bn), 2007-2017
Figure 3: Adult and Adolescent Vaccines Market to 2017, Global, Market Share By Indication (%), 2010
Figure 4: Adult and Adolescent Vaccines Market to 2017, Global, Market Share By Geography (%), 2010
Figure 5: Adult and Adolescent Vaccines Market to 2017, Global, Target Pediatric Population (‘000), 2007-2017
Figure 6: Adult and Adolescent Vaccines Market to 2017, Global, Target Adult Population (‘000), 2007-2017
Figure 7: Adult and Adolescent Vaccines Market to 2017, Global, Immunization Coverage (%), 2007-2009
Figure 8: Adult and Adolescent Vaccines Market to 2017, Global, Unmet Need, 2010
Figure 9: Adult and Adolescent Vaccines Market to 2017, Global, Drivers and Barriers, 2007-2017
Figure 10: Adult and Adolescent Vaccines Market to 2017, the US, Revenues ($bn), 2007-2017
Figure 11: Adult and Adolescent Vaccines Market to 2017, the US, Immunization Schedule, 2010
Figure 12: Adult and Adolescent Vaccines Market to 2017, the US, Vaccine Development and Approval Process, 2010
Figure 13: Adult and Adolescent Vaccines Market to 2017, the US, Vaccine Procurement, 2010
Figure 14: Adult and Adolescent Vaccines Market to 2017, Europe, Revenues ($bn), 2007-2017
Figure 15: Adult and Adolescent Vaccines Market to 2017, the UK, Immunization Schedule, 2010
Figure 16: Adult and Adolescent Vaccines Market to 2017, France, Immunization Schedule, 2010
Figure 17: Adult and Adolescent Vaccines Market to 2017, France, Distribution of Vaccine Administration by Sector, 2010
Figure 18: Adult and Adolescent Vaccines Market to 2017, Germany, Immunization Schedule, 2010
Figure 19: Adult and Adolescent Vaccines Market to 2017, Germany, Distribution of Vaccine Administration by Sector, 2010
Figure 20: Adult and Adolescent Vaccines Market to 2017, Italy, Immunization Schedule, 2010
Figure 21: Adult and Adolescent Vaccines Market to 2017, Spain, Immunization Schedule, 2010
Figure 22: Adult and Adolescent Vaccines Market to 2017, Spain, Distribution of Vaccine Administration by Sector, 2010
Figure 23: Adult and Adolescent Vaccines Market to 2017, Rest of the World, Revenues ($bn), 2007-2017
Figure 24: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Revenues ($bn), 2007-2017
Figure 25: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Annual Cost of Vaccination ($), 2007-2017
Figure 26: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Target Population (‘000), 2007-2017
Figure 27: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Revenues ($bn), 2007-2017
Figure 28: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Annual Cost of Vaccination ($), 2007-2017
Figure 29: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Target Population (‘000), 2007-2017
Figure 30: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Number of Doses Produced, 2000-2010
Figure 31: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Sales by Channel (%), 2009
Figure 32: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Vaccines Produced by Manufacturer, 2009-2010
Figure 33: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Revenues ($bn), 2007-2017
Figure 34: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Annual Cost of Vaccination ($), 2007-2017
Figure 35: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Target Population (‘000), 2007-2017
Figure 36: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Revenues ($m), 2007-2017
Figure 37: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Annual Cost of Vaccination ($), 2007-2017
Figure 38: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Target Population (million), 2007-2017
Figure 39: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Revenues ($m), 2007-2017
Figure 40: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Annual Cost of Vaccination ($), 2007-2017
Figure 41: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Target Population (million), 2007-2017
Figure 42: Adult and Adolescent Vaccines Market to 2017, Market Share Analysis (%), 2009
Figure 43: Adult and Adolescent Vaccines Market to 2017, Market Share Analysis (%), 2010
Figure 44: Adult and Adolescent Vaccines Market to 2017, Strategic Consolidations (%), 2009-2011
Figure 45: Adult and Adolescent Vaccines Market to 2017, M&A by Indication (%), 2009-2011
Figure 46: Adult and Adolescent Vaccines Market to 2017, M&A by Year (%), 2009-2011
Figure 47: Adult and Adolescent Vaccines Market to 2017, M&A by Geography (%), 2009-2011
Figure 48: Adult and Adolescent Vaccines Market to 2017, M&A by Value (%), 2009-2011
Figure 49: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Indication (%), 2009-2011
Figure 50: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Year (%), 2009-2011
Figure 51: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Geography (%), 2009-2011
Figure 52: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Value (%), 2009-2011
Figure 53: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Indication (%), 2009-2011
Figure 54: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Year (%), 2009-2011
Figure 55: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Geography (%), 2009-2011
Figure 56: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Value (%), 2009-2011

“Adult and Adolescent Vaccines Market to 2017 - Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010” provides insights into the global vaccines market forecast until 2017. The report provides an in-depth analysis of five vaccines, which include pneumococcal, seasonal flu, human papillomavirus, hepatitis A and hepatitis B. The report also examines the immunization schedules for the covered vaccines. In addition, the report also includes insights into the vaccines R&D pipeline. GBI Research's analysis shows that the overall global vaccines market was valued at $28 billion in 2010. The market is expected to witness growth at a CAGR of 11.5% for the forecast period, and will reach $56.7 billion by 2017. The global market revenues are expected to increase due to the introduction of new molecules which are currently in the regulatory filing stage, and those in the later stages of development.

It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by a team of industry experts.

By 2017, the Global Vaccines Market is Expected to Generate More than Twice the Annual Revenue of 2010

The global vaccines industry was valued at $28 billion in 2010, and is expected to reach $56.7 billion in 2017, at a Compounded Annual Growth Rate (CAGR) of 11.5%. The vaccines market, which was once considered a low-profit segment of the top players' portfolios, showed a turnaround after the resounding success of Prevnar, the first blockbuster vaccine. The ability of vaccines to generate high revenues and profits despite being priced at a premium has proven attractive to both existing players in the market and to big pharmaceutical companies who have been watching the development of the market with interest.

The increase in revenues and growth rates came at a time when the pharmaceutical industry was under huge pressure from patent expiries and weakened pipelines. The pharmaceutical industry has been intent on strengthening their revenue streams and streamlining operations through lay-offs and shutdowns of manufacturing and R&D operations. The success of premium priced vaccines such as Prevnar13 has prompted big pharmaceutical players such as Pfizer and AstraZeneca to invest in the vaccines industry, which promises safe revenues due to a lack of threat from generics."

- Novartis
- Pfizer
- Merck
- SP-MSD
- GSK Bio
- Sanofi

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

• Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth
• World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast
• Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake
• Opportunity Analysis of H1N1 (swine flu) Vaccination Market
• Seasonal Influenza Vaccines Market in Top Seven Countries to 2018 - Next Generation Quadrivalent Vaccines to Dominate the Market by Offering Broader Protection via Single Dose
• Global Vaccine Pipeline Capsule - 2012
• Emerging Microbiology Tests and Companies Developing New Technologies and Products
• Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates
• Influenza Vaccines 2012
• Analysis of Emerging Nucleic Acid Testing Assays And Strategic Profiles of Leading Suppliers